HC Wainwright Issues Optimistic Estimate for BLFS Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities research analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of BioLife Solutions in a research note issued to investors on Thursday, July 23rd. HC Wainwright analyst Y. Chen now forecasts that the medical equipment provider will earn ($0.01) per share for the quarter, up from their prior estimate of ($0.02). HC Wainwright currently has a “Neutral” rating and a $31.00 target price on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for BioLife Solutions’ FY2026 earnings at $0.03 EPS.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a report on Friday, July 17th. Jefferies Financial Group downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $30.00 to $31.00 in a report on Thursday. TD Cowen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and lowered their target price for the company from $33.00 to $31.00 in a research note on Wednesday, July 22nd. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 12th. Finally, Stephens reaffirmed an “equal weight” rating and issued a $31.00 price objective (down from $32.00) on shares of BioLife Solutions in a report on Monday. One investment analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioLife Solutions currently has an average rating of “Hold” and an average target price of $31.38.

BioLife Solutions Stock Down 0.6%

NASDAQ:BLFS opened at $29.79 on Monday. The business’s 50 day moving average is $27.09 and its two-hundred day moving average is $23.56. BioLife Solutions has a 52 week low of $17.86 and a 52 week high of $32.23. The company has a market cap of $1.46 billion, a PE ratio of -372.33 and a beta of 1.94.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, topping the consensus estimate of $0.01 by $0.03. The business had revenue of $27.50 million for the quarter, compared to analysts’ expectations of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds have recently modified their holdings of the stock. Tudor Investment Corp ET AL boosted its holdings in shares of BioLife Solutions by 85.2% in the third quarter. Tudor Investment Corp ET AL now owns 111,356 shares of the medical equipment provider’s stock worth $2,841,000 after buying an additional 51,217 shares during the period. Summit Creek Advisors LLC grew its holdings in shares of BioLife Solutions by 24.2% during the 4th quarter. Summit Creek Advisors LLC now owns 238,802 shares of the medical equipment provider’s stock valued at $5,774,000 after acquiring an additional 46,541 shares in the last quarter. Capricorn Fund Managers Ltd acquired a new position in BioLife Solutions in the 4th quarter worth about $9,153,000. Vanguard Group Inc. increased its stake in shares of BioLife Solutions by 4.0% during the 4th quarter. Vanguard Group Inc. now owns 3,087,386 shares of the medical equipment provider’s stock worth $74,653,000 after purchasing an additional 119,868 shares during the last quarter. Finally, Granahan Investment Management LLC raised its holdings in BioLife Solutions by 49.7% during the first quarter. Granahan Investment Management LLC now owns 722,057 shares of the medical equipment provider’s stock valued at $13,777,000 after buying an additional 239,701 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the completion of the sale, the insider directly owned 4,757,165 shares of the company’s stock, valued at $112,744,810.50. This represents a 12.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 1,200,000 shares of company stock worth $28,125,000 over the last ninety days. 2.20% of the stock is owned by corporate insiders.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.